Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Alasdair J Coles; Cary L Twyman; Douglas L Arnold; Jeffrey A Cohen; Christian Confavreux; Edward J Fox; Hans-Peter Hartung; Eva Havrdova; Krzysztof W Selmaj; Howard L Weiner; Tamara Miller; Elizabeth Fisher; Rupert Sandbrink; Stephen L Lake; David H Margolin; Pedro Oyuela; Michael A Panzara; D Alastair S Compston; CARE-MS II investigators; Per Soelberg Sørensen

doi:10.1016/S0140-6736(12)61768-1

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Alasdair J Coles, Cary L Twyman, Douglas L Arnold, Jeffrey A Cohen, Christian Confavreux, Edward J Fox, Hans-Peter Hartung, Eva Havrdova, Krzysztof W Selmaj, Howard L Weiner, Tamara Miller, Elizabeth Fisher, Rupert Sandbrink, Stephen L Lake, David H Margolin, Pedro Oyuela, Michael A Panzara, D Alastair S Compston, CARE-MS II investigators, Per Soelberg Sørensen

IKM

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

996 Citationer (Scopus)

Abstract

The anti-CD52 monoclonal antibody alemtuzumab reduces disease activity in previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety of alemtuzumab compared with interferon beta 1a in patients who have relapsed despite first-line treatment.

Originalsprog	Engelsk
Tidsskrift	Lancet
Vol/bind	380
Udgave nummer	9856
Sider (fra-til)	1829-39
Antal sider	11
ISSN	0140-6736
DOI	https://doi.org/10.1016/S0140-6736(12)61768-1
Status	Udgivet - 2012

Adgang til dokumentet

10.1016/S0140-6736(12)61768-1

Citationsformater

Coles, A. J., Twyman, C. L., Arnold, D. L., Cohen, J. A., Confavreux, C., Fox, E. J., Hartung, H-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., Miller, T., Fisher, E., Sandbrink, R., Lake, S. L., Margolin, D. H., Oyuela, P., Panzara, M. A., Compston, D. A. S., CARE-MS II investigators, & Sørensen, P. S. (2012). Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet, 380(9856), 1829-39. https://doi.org/10.1016/S0140-6736(12)61768-1

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy : a randomised controlled phase 3 trial. / Coles, Alasdair J; Twyman, Cary L; Arnold, Douglas L; Cohen, Jeffrey A; Confavreux, Christian; Fox, Edward J; Hartung, Hans-Peter; Havrdova, Eva; Selmaj, Krzysztof W; Weiner, Howard L; Miller, Tamara; Fisher, Elizabeth; Sandbrink, Rupert; Lake, Stephen L; Margolin, David H; Oyuela, Pedro; Panzara, Michael A; Compston, D Alastair S; CARE-MS II investigators ; Sørensen, Per Soelberg.

I: Lancet, Bind 380, Nr. 9856, 2012, s. 1829-39.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Coles, AJ, Twyman, CL, Arnold, DL, Cohen, JA, Confavreux, C, Fox, EJ, Hartung, H-P, Havrdova, E, Selmaj, KW, Weiner, HL, Miller, T, Fisher, E, Sandbrink, R, Lake, SL, Margolin, DH, Oyuela, P, Panzara, MA, Compston, DAS, CARE-MS II investigators & Sørensen, PS 2012, 'Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial', Lancet, bind 380, nr. 9856, s. 1829-39. https://doi.org/10.1016/S0140-6736(12)61768-1

Coles, Alasdair J ; Twyman, Cary L ; Arnold, Douglas L ; Cohen, Jeffrey A ; Confavreux, Christian ; Fox, Edward J ; Hartung, Hans-Peter ; Havrdova, Eva ; Selmaj, Krzysztof W ; Weiner, Howard L ; Miller, Tamara ; Fisher, Elizabeth ; Sandbrink, Rupert ; Lake, Stephen L ; Margolin, David H ; Oyuela, Pedro ; Panzara, Michael A ; Compston, D Alastair S ; CARE-MS II investigators ; Sørensen, Per Soelberg. / Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy : a randomised controlled phase 3 trial. I: Lancet. 2012 ; Bind 380, Nr. 9856. s. 1829-39.

@article{ccf251f938794250889452b7fcab2307,

title = "Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial",

abstract = "The anti-CD52 monoclonal antibody alemtuzumab reduces disease activity in previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety of alemtuzumab compared with interferon beta 1a in patients who have relapsed despite first-line treatment.",

author = "Coles, {Alasdair J} and Twyman, {Cary L} and Arnold, {Douglas L} and Cohen, {Jeffrey A} and Christian Confavreux and Fox, {Edward J} and Hans-Peter Hartung and Eva Havrdova and Selmaj, {Krzysztof W} and Weiner, {Howard L} and Tamara Miller and Elizabeth Fisher and Rupert Sandbrink and Lake, {Stephen L} and Margolin, {David H} and Pedro Oyuela and Panzara, {Michael A} and Compston, {D Alastair S} and S{\o}rensen, {Per Soelberg} and S{\o}rensen, {Per Soelberg}",

year = "2012",

doi = "10.1016/S0140-6736(12)61768-1",

language = "English",

volume = "380",

pages = "1829--39",

journal = "The Lancet",

issn = "0140-6736",

publisher = "TheLancet Publishing Group",

number = "9856",

}

TY - JOUR

T1 - Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy

T2 - a randomised controlled phase 3 trial

AU - Coles, Alasdair J

AU - Twyman, Cary L

AU - Arnold, Douglas L

AU - Cohen, Jeffrey A

AU - Confavreux, Christian

AU - Fox, Edward J

AU - Hartung, Hans-Peter

AU - Havrdova, Eva

AU - Selmaj, Krzysztof W

AU - Weiner, Howard L

AU - Miller, Tamara

AU - Fisher, Elizabeth

AU - Sandbrink, Rupert

AU - Lake, Stephen L

AU - Margolin, David H

AU - Oyuela, Pedro

AU - Panzara, Michael A

AU - Compston, D Alastair S

AU - CARE-MS II investigators

AU - Sørensen, Per Soelberg

PY - 2012

Y1 - 2012

N2 - The anti-CD52 monoclonal antibody alemtuzumab reduces disease activity in previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety of alemtuzumab compared with interferon beta 1a in patients who have relapsed despite first-line treatment.

AB - The anti-CD52 monoclonal antibody alemtuzumab reduces disease activity in previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety of alemtuzumab compared with interferon beta 1a in patients who have relapsed despite first-line treatment.

U2 - 10.1016/S0140-6736(12)61768-1

DO - 10.1016/S0140-6736(12)61768-1

M3 - Journal article

VL - 380

SP - 1829

EP - 1839

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9856

ER -